Michael Severino

Michael Severino joined Flagship in 2022 and serves as CEO-Partner and Chief Executive Officer of Tessera Therapeutics. Mike brings more than two decades of biopharmaceutical leadership and significant contributions to the research, development, registration, and commercialization of more than a dozen approved therapies.

Mike joined Flagship from AbbVie where he was Vice Chairman and President responsible for research and development and the corporate strategy office. During his tenure at AbbVie, Mike oversaw a rapid expansion of AbbVie’s pipeline and built critical new capabilities in areas such as genetics and genomics, computational biology, and precision medicine. Under his leadership, AbbVie achieved several important new molecular entity approvals and built leading franchises in hematologic oncology, immunology, and neuroscience.

Prior to joining AbbVie, Mike served in roles of increasing responsibility at Amgen, Inc., leading to his appointment as Senior Vice President, Global Development and Chief Medical Officer. As Senior Vice President he oversaw the company’s clinical development efforts across all therapeutic areas, including oncology, inflammation, neuroscience, cardiovascular, and metabolic disorders. Mike was previously Senior Director at Merck & Co., Inc. where he was responsible for leading research in multiple areas, including clinical genomics, molecular profiling, and experimental medicine.

Mike earned his B.S. in biochemistry from the University of Maryland, College Park, where he graduated summa cum laude and was a member of the Phi Beta Kappa Society. He earned his M.D. from the Johns Hopkins University and completed his residency and post-doctoral training at Massachusetts General Hospital and Harvard Medical School. In addition to serving on the board of Tessera as a director, Mike also serves on the Board of Directors for Avantor.